Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Teva
Boehringer Ingelheim
Argus Health
Fish and Richardson
UBS
Moodys
Novartis
Colorcon
Dow

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,369,062

« Back to Dashboard

Which drugs does patent 6,369,062 protect, and when does it expire?


Patent 6,369,062 protects RANEXA and is included in one NDA.

This patent has ninety-two patent family members in twenty-nine countries.

Summary for Patent: 6,369,062

Title: Sustained release ranolazine formulations
Abstract:A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Inventor(s): Wolff; Andrew A. (San Francisco, CA), Baker; Fiona (Dunfermline, GB), Langridge; John (Wrexham, GB)
Assignee: CV Therapeutics, Inc. (Palo Alto, CA) Syntex (USA) Inc. (Palo Alto, CA)
Application Number:09/538,337
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYesYes► Subscribe► SubscribeYY
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,369,062

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,303,607 Method for administering a sustained release ranolanolazine formulation► Subscribe
6,620,814 Sustained release ranolazine formulations► Subscribe
6,562,826 Sustained release ranolazine formulations► Subscribe
6,503,911 Sustained release ranolazine formulations► Subscribe
6,617,328 Sustained release ranolazine formulations► Subscribe
6,852,724 Sustained release ranolazine formulations► Subscribe
6,479,496 Methods for treating angina with ranolazine► Subscribe
6,525,057 Sustained release ranolazine formulations► Subscribe
6,864,258 Sustained release ranolazine formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,369,062

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine75027► Subscribe
Ukraine67793► Subscribe
TaiwanI241911► Subscribe
Turkey200101262► Subscribe
Turkey200101261► Subscribe
Slovenia1109558► Subscribe
Slovenia1096937► Subscribe
Russian Federation2002126615► Subscribe
Russian Federation2214233► Subscribe
Russian Federation2207856► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Moodys
AstraZeneca
McKesson
Cantor Fitzgerald
Cerilliant
Chubb
Boehringer Ingelheim
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot